| The Binding Site launches new immunoassay panel | Posted on 08/09/2009 in Scientific The Binding Site has announced the availability of its new immunoassay panel Hevylite, which is designed for the analysis of immunoglobulin heavy chain/light chain pairs.
Commonly used in cases where patients display multiple myeloma and B-cell dyscrasias, the equipment will join similar Binding Site product Freelite on the market, which currently sells around five million units per year worldwide.
Chief executive of the group Paul Duncan stated: "The introduction of Freelite has revolutionised the monitoring of patients with Multiple Myeloma and other B cell dyscrasias. Hevylite will further enhance the management of these patients."
This news follows The Binding Site's announcement last month that it had completed a pilot study it conducted on patients recovering from renal failure.
It found that 13 out of 19 people who received uninterrupted chemotherapy and high cut-off dialyser on serum-free light chain concentrations displayed signs of renal recovery.
 Other news stories from 08/09/2009
Read more in the Zenopa News Archive
How this news is generated
|  |
|
